Table 1
Non/Partial Response (n=59)Major Clinical Response (n=58)UVA OR (95% CI), P-valueMVA OR (95% CI), P-value
Age, mean (SD) years43 (17)37 (14)0.97 (0.95–0.99), p=0.031 per year0.97 (0.94–0.99), p=0.037
White, N (%)43 (73)37 (64)1.53 (0.70–3.34), p=0.2920.93 (0.34–2.54), p=0.882
Anti-dsDNA, mean (SD) IU/ml147 (230)142 (230)1.00 (0.99–1.00), p=0.913 per unit1.00 (0.99–1.00), p=0.518
Anti-ENA positivity, N (%)40 (68)38 (66)0.93 (0.42–2.06), p=0.8601.00 (0.39–2.57), p=1.00
Low C3 and/or C4, N (%)25 (42)24 (41)0.97 (0.46–2.06), p=0.9451.33 (0.46–3.80), p=0.599
ESR, mean (SD) mm40 (32)41 (36)1.00, (0.99–1.01), p=0.901 per unit1.00 (0.97–1.00), p=0.349
Concomitant DMARDs,N (%)41 (69)35 (60)0.67 (0.31–1.43), p=0.3010.39 (0.16–1.00), p=0.051
Global BILAG, mean (IQR)21 (8)24 (13)1.03 (0.99–1.07), p=0.093 per point1.03 (0.98–1.08), p=0.191
Total B-cell counts x 1000 mean (IQR)101 (95)138 (150)1.00 (1.00–1.01), p=0.169 per unit1.00 (1.00–1.01), p=0.103
B-cell depletion at 6 weeks, N (%)29 (49)39 (68)2.15 (0.98–4.71), p=0.0563.44 (1.25–9.48), p=0.017